Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06177028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06177028 · ClinicalTrials.gov record · last posted 2025-05-18

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

StatusNot Yet Recruiting
PhasePhase 2
Started2025-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 18, 2025 (before its estimated January 2, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as to changes in the relationship between the subject and study partner that might occur with the initiation of treatment and expectation of improvement in motor symptoms or cognition. Changes in subject/study partner interactions can impact subject mood and might introduce biases that cannot be quantified. The double-blind use of placebo will also prevent bias in the clinical and scientific assessments.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2023-12-11. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT06177028
Lead Sponsor St. Joseph's Hospital and Medical Center, Phoenix
Collaborators: Texas Tech University
Conditions Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegenerative Disease, Hereditary, Inflammation, Brain
Enrollment 45 participants
Start Date 2025-06-01
Primary Completion 2026-01-02 (estimated)
Study Completion 2027-01-02 (estimated)
Updated on ClinicalTrials.gov 2025-05-18